Jean-Pierre Bizzari

614 total citations
24 papers, 515 citations indexed

About

Jean-Pierre Bizzari is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Jean-Pierre Bizzari has authored 24 papers receiving a total of 515 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Oncology, 10 papers in Molecular Biology and 5 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Jean-Pierre Bizzari's work include Drug Transport and Resistance Mechanisms (4 papers), Brain Metastases and Treatment (3 papers) and Cancer Treatment and Pharmacology (3 papers). Jean-Pierre Bizzari is often cited by papers focused on Drug Transport and Resistance Mechanisms (4 papers), Brain Metastases and Treatment (3 papers) and Cancer Treatment and Pharmacology (3 papers). Jean-Pierre Bizzari collaborates with scholars based in France, Switzerland and Canada. Jean-Pierre Bizzari's co-authors include Laurence Kraus‐Berthier, Alain Pierré, B. Giroux, Pierre Banzet, David Khayat, M Weil, D. Khayat, Ghanem Atassi, W.J. Mackillop and Gilbert Lavielle and has published in prestigious journals such as JNCI Journal of the National Cancer Institute, Cancer Research and British Journal of Cancer.

In The Last Decade

Jean-Pierre Bizzari

24 papers receiving 501 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jean-Pierre Bizzari France 14 288 267 95 73 66 24 515
K Csóka Sweden 12 246 0.9× 207 0.8× 47 0.5× 50 0.7× 39 0.6× 19 503
H.H. Sedlacek Austria 6 419 1.5× 393 1.5× 153 1.6× 86 1.2× 59 0.9× 7 737
Ronald Drengler United States 13 296 1.0× 487 1.8× 104 1.1× 56 0.8× 17 0.3× 27 701
Beverly A. Teicher United States 15 387 1.3× 240 0.9× 79 0.8× 35 0.5× 37 0.6× 32 665
Clara Lemos Netherlands 9 451 1.6× 297 1.1× 52 0.5× 30 0.4× 66 1.0× 10 698
Darrell Nix United States 9 566 2.0× 329 1.2× 70 0.7× 59 0.8× 36 0.5× 21 876
Brenda D. Bailey United States 10 306 1.1× 172 0.6× 46 0.5× 42 0.6× 56 0.8× 12 615
Y.-H. Ling United States 13 333 1.2× 226 0.8× 84 0.9× 26 0.4× 46 0.7× 24 582
Philippe Genne France 15 368 1.3× 262 1.0× 28 0.3× 26 0.4× 37 0.6× 30 632
Elin Lindhagen Sweden 14 245 0.9× 138 0.5× 35 0.4× 77 1.1× 50 0.8× 28 505

Countries citing papers authored by Jean-Pierre Bizzari

Since Specialization
Citations

This map shows the geographic impact of Jean-Pierre Bizzari's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jean-Pierre Bizzari with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jean-Pierre Bizzari more than expected).

Fields of papers citing papers by Jean-Pierre Bizzari

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jean-Pierre Bizzari. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jean-Pierre Bizzari. The network helps show where Jean-Pierre Bizzari may publish in the future.

Co-authorship network of co-authors of Jean-Pierre Bizzari

This figure shows the co-authorship network connecting the top 25 collaborators of Jean-Pierre Bizzari. A scholar is included among the top collaborators of Jean-Pierre Bizzari based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jean-Pierre Bizzari. Jean-Pierre Bizzari is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Zeldis, Jerome B., et al.. (2010). Lenalidomide in multiple myeloma: current role and future directions. Expert Opinion on Pharmacotherapy. 11(5). 829–842. 15 indexed citations
2.
Richard, M.‐A., et al.. (1998). Combined treatment with dacarbazine, cisplatin, fotemustine and tamoxifen in metastatic malignant melanoma. Melanoma Research. 8(2). 170–174. 11 indexed citations
3.
Oum'Hamed, Zohra, et al.. (1994). [Quantitative cytological study of the activity of a new resistance modulator, S 9788, on human leukemic cells using multiparametric image analysis].. PubMed. 81(3). 203–11. 3 indexed citations
4.
Khayat, David, B. Giroux, J. Bérille, et al.. (1994). Fotemustine in the Treatment of Brain Primary Tumors and Metastases. Cancer Investigation. 12(4). 414–420. 56 indexed citations
5.
Fischel, Jean–Louis, et al.. (1993). Evaluation of the time-schedule dependency for the cytotoxic activity of the new vinca alkaloid derivative, S 12363 (Vinfosiltine). European Journal of Cancer. 29(13). 1890–1894. 2 indexed citations
6.
Fischel, Jean–Louis, et al.. (1993). Tamoxifen enhances the cytotoxic effects of the nitrosourea fotemustine. Results on human melanoma cell lines. European Journal of Cancer. 29(16). 2269–2273. 8 indexed citations
7.
Merrouche, Yacine, Sylvie Négrier, Paul Rebattu, et al.. (1993). Phase II study of fotemustine as second-line treatment after failure of immunotherapy in metastatic renal cell carcinoma. Cancer Chemotherapy and Pharmacology. 32(4). 329–331. 7 indexed citations
8.
Pierré, Alain, Theresa Dunn, Laurence Kraus‐Berthier, et al.. (1992). In vitro andin vivo circumvention of multidrug resistance by Servier 9788, a novel triazinoaminopiperidine derivative. Investigational New Drugs. 10(3). 137–148. 63 indexed citations
9.
Cros, Suzy, et al.. (1992). In vivo evidence of complete circumvention of vincristine resistance by a new triazinoaminopiperidine derivative S 9788 in P388/VCR leukemia model. Cancer Chemotherapy and Pharmacology. 30(6). 491–494. 16 indexed citations
10.
11.
Khayat, D., Jean-Pierre Bizzari, Karl Reinhard Aigner, et al.. (1991). Fotemustine (S 10036) in the Intra-Arterial Treatment of Liver Metastasis from Malignant Melanoma. American Journal of Clinical Oncology. 14(5). 400–404. 13 indexed citations
12.
Laquérrière, A., et al.. (1991). Nitrosoureas lomustine, carmustine and fotemustine induced hepatotoxic perturbations in rats: Biochemical, morphological and flow cytometry studies. European Journal of Cancer and Clinical Oncology. 27(5). 630–638. 22 indexed citations
13.
Atassi, Ghanem, et al.. (1991). Characterization of the pharmacological antitumor effects of S 12363, a new vinca alkaloid.. PubMed. 11(2). 975–80. 2 indexed citations
14.
Jacquillat, C, David Khayat, Pierre Banzet, et al.. (1990). Chemotherapy by fotemustine in cerebral metastases of disseminated malignant melanoma. Cancer Chemotherapy and Pharmacology. 25(4). 263–266. 52 indexed citations
15.
Bonneterre, J., E Grosshans, P. Fumoleau, et al.. (1990). Combination chemotherapy of dacarbazine and fotemustine in disseminated malignant melanoma. Cancer Chemotherapy and Pharmacology. 27(2). 81–84. 23 indexed citations
16.
Meulemans, A., et al.. (1989). Permeability of two Nitrosoureas, Carmustine and Fotemustine in Rat Cortex. Chemotherapy. 35(5). 313–319. 23 indexed citations
17.
Boutin, Jean A., et al.. (1989). Effects of the new nitrosourea derivative, fotemustine, on the glutathione reductase activity in rat tissues in vivo and in isolated rat hepatocytes. European Journal of Cancer and Clinical Oncology. 25(9). 1311–1316. 16 indexed citations
18.
Khayat, D., Jean-Pierre Bizzari, M. Frénay, et al.. (1988). Interim Report of Phase II Study of New Nitrosourea S 10036 in Disseminated Malignant Melanoma. JNCI Journal of the National Cancer Institute. 80(17). 1407–1408. 20 indexed citations
19.
Khayat, D., François Lokiec, Jean-Pierre Bizzari, et al.. (1987). Phase I clinical study of the new amino acid-linked nitrosourea, S 10036, administered on a weekly schedule.. PubMed. 47(24 Pt 1). 6782–5. 47 indexed citations
20.
Bizzari, Jean-Pierre & W.J. Mackillop. (1985). The estimation of self-renewal in the clonogenic cells of human solid tumours: A comparison of secondary plating efficiency and colony size. British Journal of Cancer. 52(2). 189–195. 9 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by K Csóka Breakdown of academic impact, for papers by H.H. Sedlacek Breakdown of academic impact, for papers by Ronald Drengler Breakdown of academic impact, for papers by Beverly A. Teicher Breakdown of academic impact, for papers by Clara Lemos Breakdown of academic impact, for papers by Darrell Nix Breakdown of academic impact, for papers by Brenda D. Bailey Breakdown of academic impact, for papers by Y.-H. Ling Breakdown of academic impact, for papers by Philippe Genne Breakdown of academic impact, for papers by Elin Lindhagen
Rankless by CCL
2026